Aspirin tablets 81mg (ASPIRIN® 81mg) Kharazmi , In- Vivo Bioequivalence in Iranian healthy volunteers.
Not Applicable
Recruiting
- Conditions
- In this study the bioquivalence of test and brand of Aspirin will evaluated..
- Registration Number
- IRCT20200105046010N10
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General health(liver, heart, kidney)
Body mass index(18-28)
Informed consent
Age(18-60)
Exclusion Criteria
Smoking
A history of cardiovascular disease
A history of liver & kidney disease
Pregnancy
Alcohol & Drug addiction
Hypersensitivity to the drug
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug analysis in plasma or whole blood. Timepoint: Sampling times in this study will be 0 , 1, 2 , 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 24 hours. Method of measurement: High Performance Liquid Chromatograpy(HPLC)- Mass -Mass Spectrometer detector (MS/MS).
- Secondary Outcome Measures
Name Time Method